Received: 17 December 2017
Accepted: 28 August 2018
First Online: 4 October 2018
Ethics approval and consent to participate
: This study was conducted in compliance with the principles of the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (m05003) and registered as a clinical trial (P-GDM-Lina: A pilot study on prevention of glucocorticoid-induced diabetes mellitus by linagliptin, Japan, #UMIN000015588). Written informed consent was obtained from each patient by the attending physician or investigator before any screening or inclusion procedure.
: Jun Wada received speaker honoraria (less than $10,000 each) from Astellas, Boehringer Ingelheim, Novartis, and Tanabe Mitsubishi, and receives grant support (more than $10,000 each) from Astellas, Bayer, Chugai, Daiichi Sankyo, Kissei, Kyowa Hakko Kirin, MSD, Otsuka, Teijin, Torii, Pfizer, Takeda, and Taisho Toyama.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.